🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
ALK-Abelló A/S (CPH:ALK.B)
Denmark flag Denmark · Delayed Price · Currency is DKK
242.80
-2.20 (-0.90%)
Nov 20, 2026, 11:21 AM CET
← View all transcripts

Jefferies Global Healthcare Conference

Nov 18, 2026

Summary

Quarterly growth was led by tablets, with pediatric launches, new markets and Europe supporting momentum. Pipeline priorities include peanut AIT Phase III and neffy, while disciplined BD and Germany rebate mitigation remain in focus.

Ben Jackson
European Biopharma Analyst, Jefferies

Brilliant. Thank you all for coming. This is day three of the Jefferies Healthcare Conference. My name is Ben Jackson. I am one of the European biopharma analysts here at Jefferies. It is a pleasure today to be joined by the ALK team. We have Peter, CEO, as well as Per, head of IR. Appreciate you guys coming down just a day after your earnings as well. It is a quick turnaround, but I appreciate you both being here. Before we jump into the Q&A, shall I just give you a couple of 30 seconds—

Peter Halling
CEO, ALK-Abelló

Yeah.

Ben Jackson
European Biopharma Analyst, Jefferies

—just to give a quick brief overview of the update you provided yesterday and the confidence you have going forward?

Peter Halling
CEO, ALK-Abelló

Yeah, absolutely. Thank you, Ben. Thanks for joining. Yesterday we announced the quarter result. We had yet another quarter for ALK where we grew 15% overall, but 35% of our tablets business, which is the core of our business and a big growth driver for the company. On top of it, we saw it being broad-based. We saw it across our different markets, and it is an increasing contributor both to the top and the bottom line. When we look ahead, we still see tablets, especially driven by the children indications, driven by new geographies, and a continued growth in Europe as key drivers for the business.

The good news is, and I know we will get back to it, is that we are also really starting to build new growth engines for the company, including in anaphylaxis with neffy, and also in the future with food allergies, where we are working on both AIT and also anti-IgEs.

Ben Jackson
European Biopharma Analyst, Jefferies

Look, it's been a great year, I guess, for financial results. Couple of upgrades, done very well, pre-announced into 3Q. What were the biggest change that led to that, the latest guidance upgrade, and what uncertainties are left that we have to think about into the fourth quarter?

Peter Halling
CEO, ALK-Abelló

Yeah, good question. Firstly, it's not because we are conservative by nature. I think we've been fairly ambitious throughout the year. But we've seen that our launches, especially with children, tablets, the markets, we've seen continued progression, and also on top of what we had anticipated. So that's been a very strong driver. Again, back to what I said earlier on in Europe, we're seeing strong growth broad-based, and we're also seeing that some of the new markets have been growing nicely. Then, when we look ahead for the rest of the year, it's clear that we are able to narrow, because we have more insights, both in terms of the initiation season, which is important to the company.

For those of you who don't know the initiation season, the pollen season has been fairly strong across the world, especially for tree pollen, and that gives us a good idea when we then see the number of visits in the fall to doctors. Secondly, we have more insight there. But then secondly, obviously, we always have the supply chain, the deliveries across markets, especially to Asia, that can have an effect. Now we have more confidence in both, and that has also given us a certainty that we are going to deliver some result.

Ben Jackson
European Biopharma Analyst, Jefferies

I guess the target that you set previously was the over 10% top-line growth, which it's fair to say you've exceeded that fairly well so far each year. Going forward into the next two years, what level of confidence do you have that that should be sustained, and what are the key drivers? Is it again tablets and pollen?

Peter Halling
CEO, ALK-Abelló

Yeah, I think it's important to say that when I joined the company a little more than three years ago, we basically asked ourselves, can we actually really deliver high double-digit growth on the tablets, more than 10% across the business? I think we've been able to prove that with the children indication launches, where we still have markets that we are launching into.

Ben Jackson
European Biopharma Analyst, Jefferies

Yeah.

Peter Halling
CEO, ALK-Abelló

That that would be a driver for us. I think we've confirmed that, and that also gives us confidence going forward. I think on top of it, we've seen that the anaphylaxis portfolio has done quite well, particularly actually on the auto-injectors, but even with neffy now starting to contribute to the business, and that also gives us a confidence. Then you can say on the bottom line, where we guided on the 25% as a target and exceeded, we more or less doubled it in three years. We are keeping it and sustaining it at high levels because we are getting the momentum from the mix effect of the business. Tablets are a very profitable business for us, but we're also getting more leverage on our whole supply chain and manufacturing setup.

Ben Jackson
European Biopharma Analyst, Jefferies

I guess it wouldn't be a Jefferies Healthcare Conference without bringing up politics. Typically, we would talk about MFN and U.S. pricing with companies, but instead, I think we talk a lot more about the German rebates and what's going on there.

Peter Halling
CEO, ALK-Abelló

Yeah.

Ben Jackson
European Biopharma Analyst, Jefferies

Clearly, still very confident in strong growth despite that. How are the conversations progressing in and around with the German government that potentially could lead to an offset of that headwind, which I think, from outside, we've fairly well baked in here?

Peter Halling
CEO, ALK-Abelló

Yeah. It's fairly opaque, to be honest, what's going on in Germany. We are quite certain of the level of the rebate, the 15.5% moving from 7%. Do remember, over the years, as you know, it's been fluctuating between 7% and 16%. Now it's back to the 15.5%. We had anticipated an increase. We've been looking into what are the options. There's a lot on the table in terms of how you could potentially reduce it.

Ben Jackson
European Biopharma Analyst, Jefferies

Yeah.

Peter Halling
CEO, ALK-Abelló

There's also uncertainty in which form and how it's going to impact the company. So we are actually operating based on a model where we say we take the full account into our planning, but we know, for instance, that we can renegotiate some of the contracts we have with insurance companies in Germany, because they are getting both money from the government and they're also getting rebates from us, and we want to avoid that double-dipping. So that's a clear driver for us. We can control that. We are obviously controlling the investments levels on the company. Just to be very clear, Germany remains a growth market for ALK, also going forward. It's a very, very interesting market. We have a lot of work ahead of us, and the opportunity.

Even though we don't get the full impact of the rebate, then I think we can still mitigate in a manageable way. So we're not too concerned.

Ben Jackson
European Biopharma Analyst, Jefferies

Good. Reassuring.

Peter Halling
CEO, ALK-Abelló

Reassuring.

Ben Jackson
European Biopharma Analyst, Jefferies

Before we jump into specific product areas, I do want to touch on capital allocation a little bit. I think it is something that perhaps we are talking about a bit more, given the strong position that you are in here. How important is business development and M&A to your strategy going forward? We have obviously seen a sublicense agreement come into effect as of yesterday.

Peter Halling
CEO, ALK-Abelló

Yeah.

Ben Jackson
European Biopharma Analyst, Jefferies

Pretty new. Talk to me about BD and how you think about capital.

Peter Halling
CEO, ALK-Abelló

Yeah, let me start maybe with giving everyone the capital allocation principles we have. We are quite disciplined around it. We said, as a company, we are investing organically in the business. We are a growth company. We have a significant amount of growth opportunities organically. But we actually believe that BD can be a meaningful way of supporting that ambition. We see areas like food, we see areas even anaphylaxis, where you saw the neffy deal. We also could imagine in respiratory that there could be opportunities for the company. We are exploring those on an ongoing basis. We are also saying we are not going to pile cash in the company.

I know that some investors and some analysts will say we are piling cash currently, but we will be back early next year as part of the annual report, talking about how do we actually distribute cash and what are the intent. But I will say we are going to be very disciplined around it. Also, when you look at BD&L and M&A potentially, because we are in a position where we do not have the patent expiries. We want to look at how do we actually amplify and strengthen our portfolio across our different areas, and we think as a company, we are in a unique position to really build that. It has to make sense.

We are not looking for transformative bets that are changing the company because we don't need to, but we are looking for bets that are supplementing what we're doing and the growth journey we are on, and there we still see opportunities.

Ben Jackson
European Biopharma Analyst, Jefferies

Yeah.

Peter Halling
CEO, ALK-Abelló

That's the best answer I can give you.

Ben Jackson
European Biopharma Analyst, Jefferies

That's a great answer, and it's as far as I can probably push you on that, so we're waiting for you. Thinking a little bit about tablets then, you commented briefly on kind of the pollen season, a little bit on the initiation season, but could you perhaps touch on what you've seen from the early signs from that initiation season? And what kind of visibility does that give you over a multi-year runway, given the way that these tablets are typically taken?

Peter Halling
CEO, ALK-Abelló

Yeah. When you think about our patient pool, typically it's a three-year treatment when we talk about AIT. Venom is a slightly different story. But AIT, especially when you talk about the pollen seasons. We build up every year, look at it as a staircase. Group one, the first cohort comes in one year, they stay. Next year, you have a new one building on. Third year, a new one. Each year, what is impacting it is how many patients leave the treatment, and how many patients are coming in during the initiation seasons. When we talk about the initiation seasons, it impacts the number of new patients coming into our business. This year, we've seen across Europe that tree pollen has been quite high, and that typically bodes well for the season.

We have some leading indicators in terms of the pollen, also the antihistamine usage, et c. Grass pollen, which is the second one, has been more normal, so pretty standard for the year. We are obviously trying to strengthen it by doing marketing initiatives. Thirdly, we are looking mostly at the house dust mite. That is not a seasonal thing, it is more broad-based, and there we still see high numbers coming in. On top of it for us, especially these years, the children part is important because expanding the label to children means that we are treating the patients that needs our treatment the most early on. To give you an example, if you think about asthma, children with asthma not going on treatment, or sorry, children with allergy not going on treatment have a 7x higher risk of developing asthma.

The early treatment is so important, and that also means that we see higher adherence. We see both the regulatory bodies being more interested, and the patient, and especially the patient's parents, making sure that they take the treatment. That is important to us because it gives you an idea that patients will stay more and longer on our treatment, and that is also part of why we are seeing better numbers.

Ben Jackson
European Biopharma Analyst, Jefferies

I guess a good evidence point of that has been Japan, whereby the percentage of total patients on treatment that are pediatrics is very high in comparison to the rest of the world. Where are we in Europe today, and how high could that go? Is Japan a bellwether, or is there different environments there?

Peter Halling
CEO, ALK-Abelló

As you can imagine, Ben apparently knows our business quite well. He has all the details. Why don't you give the answer yourself, Ben? Because I might get involved. No, no. You are right. In Japan, we typically see, from an AIT standpoint, Japan is in many ways an ideal market. You have a very high propensity in the population, people suffering from allergy. We hear numbers from our partner Torii in Japan of up to 40% suffering from cedar allergy. This also means that it is very high on the political agenda. On top of it, there is a system in Japan which basically means that doctors get trained early on in terms of treating allergy patients. There is a lot of focus also from a cultural standpoint about finishing what you start.

So that gives us a very high adherence compared to Europe, and even to the U.S. In Europe, it might be around half or even less in terms of adherence what we see in Japan, in the U.S., even lower. And especially with the children, we have seen that in average it has been 17 percentage points- 20 percentage points higher in terms of what we have seen elsewhere. That gives you quite a lot of idea. When you already have the customer in your shop, you want them to stay, and especially stay throughout the full treatment, also for the benefit of the patient. And if we could transfer that number to Europe and even to North America, that would actually have a quite meaningful impact on our business. So, we are working on it, and we are also seeing it to some extent in the numbers. Early days.

Ben Jackson
European Biopharma Analyst, Jefferies

Early days. And I guess the other way to think about it is on the total penetration of patients with allergy, well, respiratory allergies.

Peter Halling
CEO, ALK-Abelló

Yeah.

Ben Jackson
European Biopharma Analyst, Jefferies

What is the high watermark in your markets? Can you drive that higher? Is that the opportunity here, or is the opportunity bringing the under-penetrated markets towards that high watermark?

Peter Halling
CEO, ALK-Abelló

Yeah. It is both, right? One is, take a market like Germany. We often talk about it, but it is far from a saturated market. You still have patients that are not being treated there, a vast amount of children. You still have new prescribers coming in. You have even competition, you could say. Globally, we have around 50% market share. There is still plenty of room to grow there. Then you have new markets, U.K. being an excellent example. Less than 10 patients per 100,000 are getting treated here in the U.K. If that were on par with some of our other markets, this market would have a same size as a market like France, at least. You can add food allergies, anaphylaxis on top of it. So, plenty of room.

But the thing around AIT is that we need to make sure it goes hand in hand with market access and regulations, reimbursement, et c. That is why that it is a slow grinding machine, if you call +10% growth slow. But compared to the potential, there is still so much room. In other words, we normally, when we talk about it, we say from a big picture, we have penetrated around 10% - 15% of the global market potential. So, plenty of room for many, many years. Take another 100 years, and I can tell you we have much, much, much, much stronger plans for penetrating faster than that. So, still room and still opportunity.

Ben Jackson
European Biopharma Analyst, Jefferies

China is a pretty big market as well. You have got a partner, GenSci, over there looking to capitalize on that. How excited are you about that end market potential? Remind us what kind of economics you get from the partner—

Peter Halling
CEO, ALK-Abelló

Yeah.

Ben Jackson
European Biopharma Analyst, Jefferies

—if you can.

Peter Halling
CEO, ALK-Abelló

Yes. GenSci is our partner in China. GenSci is a very successful company coming out of growth hormones, where they successfully built a market-leading position. They have a similar setup in terms of how they approach the hospitals in China and the clinics, like we have, and therefore, they were a very relevant partner for us in China. By engaging in that partnership, we have been able to access almost tenfold the number of market reps or sales reps that we have in our own sales team. Secondly, we have a partner who really understands the Chinese market. It was not that we did not have success in China, but we could really see that we would benefit from this. In China alone, there is around 35,000 hospitals and clinics, and we were basically around 1,000 of them, so we still had some way to go.

That went hand in hand. Secondly, with ACARIZAX now going into approval after our successful phase III trial in China, we really see that GenSci can play a key role in getting it into the market much faster than we could alone. In terms of the deal, the deal is basically what we call our COGS plus, and then we get sales milestones and some royalty on top. It is a very good deal for both parties. I would say the choice of GenSci, it was a long process, but we really found a partner who have already, during the initial work, proven their worth.

Ben Jackson
European Biopharma Analyst, Jefferies

Got it. Food allergy as well. There is a lot to talk about here, but I guess if we keep it concentrated at the moment on the peanut allergy, you announced yesterday that you have submitted that clinical trial application to FDA. How long do we have to wait for to see that phase III trial start, and how much do we know about the design of that? Therefore, the question ultimately from us on a simple perspective that you probably cannot tell us is when should we expect some results from that?

Peter Halling
CEO, ALK-Abelló

Let me start by maybe just the timeline, and then Per, if you jump in a little bit to the design. But timeline-wise, the aim is basically that we get a go before Christmas, and then we can get initiated as planned—

Ben Jackson
European Biopharma Analyst, Jefferies

Yeah.

Peter Halling
CEO, ALK-Abelló

—towards the end of the year. It sits with the FDA now. We have been through the round of questions, as usual, that any companies go through, and we have responded to that, and hopefully we can now move forward. But maybe a little bit on the design, Per?

Per Plotnikof
Head of Investor Relations, ALK-Abelló

Yeah. So, thank you, Peter. So the design of the peanut study that we are working with now builds on the design and the results that we saw in our phase II study earlier this year. This was a very successful proof of concept study where we identified the dose that we will move into phase III with, also the profile, the up-titration steps. In contrast to the phase II trial, where we looked for an early signal of onset of action, here we are now, sorry, after six months here, we are now looking into a 12-months treatment duration. And we would expect that the treatment effect would build further over these additional six months of treatment compared to the phase II study. That was actually quite strong. I mean, it was the first time we saw such strong results after such short treatment periods.

So we are quite encouraged. We saw effect across multiple endpoints, et c. So that gave us a strong basis for designing the phase III study that we are now just waiting for the final sign-off on, and then we can share with you the exact details on it.

Ben Jackson
European Biopharma Analyst, Jefferies

Yeah.

Per Plotnikof
Head of Investor Relations, ALK-Abelló

But it builds on the results and the learnings from there.

Ben Jackson
European Biopharma Analyst, Jefferies

Got it. And then I guess there's a lot of large pharmas as well looking at food allergy. You are not the only ones, it is fair to say. A lot of what other people are doing is around either biologic work, either around patch therapies. What is different about the program that you are developing here that differentiates it in that market?

Peter Halling
CEO, ALK-Abelló

Yeah. When you look at food allergy, a lot when we talk about anti-IgEs, which is basically where you see big pharma moving in. Firstly, it is very much around how you block the symptoms and how you keep the symptoms down, right? So it is a lifelong treatment for the patient, and it is basically continuous injections, primarily on an ongoing basis. That is what we would call blockers or symptomatic treatment. Then you have AIT, which is the allergy immunotherapy. This is where we aim at modifying the immune system so you can tolerate the exposure to the allergen. In this case, where our program in AIT is on peanut, so it is a very specific targeted allergen that we are focusing in on.

We believe that this is half the market because a lot of especially younger patients will be looking for disease modifying rather than lifelong injections. We actually think we have the technology, as Per just talked about, but also potentially to expand beyond peanut. This could be tree nuts, it could even be into other areas that could be of interest. Then we also have a biologic ourselves.

Ben Jackson
European Biopharma Analyst, Jefferies

Yeah.

Peter Halling
CEO, ALK-Abelló

This is ALK-014. We are moving it into phase I. I cannot go into the details today, but we do believe that it is different. It is what we would call a third generation. So you have obviously XOLAIR now, and then you have a lot of new ones coming in. We believe there are some additional benefits to what we do that could be relevant in this space. So now we move it into phase I, and we can share more on the details there and the data pack when we get closer. So we are playing on both horses. Then on the patches and other technologies, do remember that today, food allergy, the solution for people suffering from it is basically to stay away or to get XOLAIR. That is pretty much what is out there.

There is some OIT in the U.S., but that is a cumbersome process. Palforzia, which used to be in the market, was not there. You have a market of around 200 million people suffering from this. Very, very few get treatment today. There is ample room for all companies. Actually, I think we encourage all to get into the market because we need to develop it. We need jointly to develop this market. We believe we have solutions that plays into multiple avenues in that market going forward, but we certainly also believe that others will bring in innovation that is relevant. But there is ample room, as I say, for everyone to grow. So we are not concerned on the contrary. We need to get it developed because the patient needs are there, and there is a very, very big request for it.

So I also know you are going to ask about market sizes, et c. I guess when big pharma moves in, it tells you there is a big potential. I think that is the best answer to that one.

Ben Jackson
European Biopharma Analyst, Jefferies

I will try again next year.

Peter Halling
CEO, ALK-Abelló

Yeah, exactly.

Ben Jackson
European Biopharma Analyst, Jefferies

If we finish on neffy then. Obviously, some interesting numbers put up yesterday in and around growth that you have seen. What would you highlight as the key proof points that this market is beginning to develop as a needle-free nasal adrenaline, and what evidence that going forward that should continue on that momentum?

Peter Halling
CEO, ALK-Abelló

Yeah. I look at neffy and also the way we have been seeing the business as a little bit of a snowball. It is rolling, and we clearly see that this product has merits. When we do our market research, not only by us, but even by analysts like you and many others, it is very clear, if you bring in a new patient and you ask them whether they prefer an auto-injector or they prefer an intranasal device, more than 95% chooses the intranasal device. And especially when you talk young children, and children, and even teenagers. This is very clear. The same for caregivers in terms of bystander administration, et c., is very strong. There is no doubt the demand is there, the need is there. But you have to go through all the 40-year-old way of doing things. How do you prescribe?

How do you break into prescriber patterns? You have to get market access in place. Here in the U.K., we need to get through all the formularies, et c. It is a stepwise approach. Long story short, neffy, as we see it, are going to transform, or intranasal devices are going to transform the adrenaline market, no doubt about it. The question is how fast and how much. But again, it is a very good example of a market that is vastly under-penetrated. Around 10% of the people who are supposed to carry an auto-injector are carrying one. You have 90% out there that are not.

Ben Jackson
European Biopharma Analyst, Jefferies

Yeah.

Peter Halling
CEO, ALK-Abelló

I think there is ample room. It is not just a market share gain in the existing business, it is a conversion and a transformation that we are building on. And I personally believe, and we as a company believe this is where we see significant opportunity in many, many years to come. But it is going to take a bit of time.

Ben Jackson
European Biopharma Analyst, Jefferies

Yeah, for sure. I guess a nearer term thing for neffy is perhaps the phase II-B interim results for the acute flares of CSU.

Peter Halling
CEO, ALK-Abelló

Yes.

Ben Jackson
European Biopharma Analyst, Jefferies

A lot of words in there. How excited are you about that? Is that something that you think could be a big potential?

Peter Halling
CEO, ALK-Abelló

Yeah.

Ben Jackson
European Biopharma Analyst, Jefferies

What are the considerations for development there?

Peter Halling
CEO, ALK-Abelló

Well, you could say when you look at CSU acute flares, today there are no emergency treatments. That means for patients getting this sudden swelling and these sudden rashes that are very painful, there are not solutions today. You actually have anti-IgEs or corticosteroids that can help over a while, but they are not going to remove it immediately. It looks like, and this is what we are testing in the phase II-B together with ARS Pharma, that this is working, this issue. There is no doubt the potential is substantial in this, but it is also a completely new market that needs to be developed from scratch. So exciting, but also a lot of work ahead. We are very positive, but we need to see the full potential.

Ben Jackson
European Biopharma Analyst, Jefferies

We could talk for much longer, but we are going to have to cut it there. Thank you so much both for joining. Thank you all for joining us. If you have any questions, please feel free to reach out. Thank you.